Accentia Biopharmaceuticals Inc

Accentia Biopharmaceuticals — Corporate Update (October 2007)

35 slides from Accentia Biopharmaceuticals's corporate update, Oct 9, 2007

  1. Slide 1: SinuNase

    SinuNase Frank E. O’Donnell, Jr, MD Chairman and CEO SinuNase Exhibit 99.1

  2. Slide 2: Disclosure statement

    2 Disclosure statement Disclosure statement This presentation includes forward-looking statements including statements regarding the timing and outcome of clinical trials, potential regulatory approvals, future demand for and sales of our products and the future development of new products. These st

  3. Slide 3: Chronic sinusitis

    3 Chronic sinusitis Chronic sinusitis Symptoms • Chronic nasal obstruction • Chronic post-nasal drip and rhinorrhea • Chronic periocular headaches • Recurrent bouts of acute bacterial sinusitis Signs • Intranasal polyps on endoscopy • Mucosal thickening on CT of sinuses Costs • $5.8 Billion per year

  4. Slide 4: Chronic Sinusitis: Mucosal changes due to eosinophilic infiltration of tissue

    4 Chronic Sinusitis : Mucosal changes due to eosinophilic infiltration of tissue…fungus is non-invasive Chronic Sinusitis : Mucosal changes due to eosinophilic infiltration of tissue…fungus is non-invasive Eosinophils in tissue migrate into mucus to attack fungus Polyps by endoscopy Sinus mucosal th

  5. Slide 5: How bad is it? Impact on Quality of Life

    5 How bad is it? Impact on Quality of Life is worse than back pain, congestive heart failure, chronic obstructive pulmonary disease How bad is it? Impact on Quality of Life is worse than back pain, congestive heart failure, chronic obstructive pulmonary disease CS impact on bodily pain scores (lower

  6. Slide 6: How big is the market? 10% of population has chronic sinusitis

    6 How big is the market ? 10% of population has chronic sinusitis How big is the market ? 10% of population has chronic sinusitis 2.5 Under ENT Care Post-Surgery CRS Moderate-to- Severe CRS Diagnosed Total with CRS

  7. Slide 7: Prior management of CS

    7 Prior management of CS Prior management of CS Hampered by lack of understanding of the pathogenesis No approved pharmaceutical Nothing has ever been in phase 3 study Development pipeline: intranasal antibiotic Functional endoscopic surgery •Improve airway and sinus drainage by excising polyps •Imp

  8. Slide 8: A paradigm shift: host sensitivity to a common mold (Alternaria)

    8 A paradigm shift: The cause of chronic sinusitis is host sensitivity to a common mold (Alternaria) A paradigm shift: The cause of chronic sinusitis is host sensitivity to a common mold (Alternaria) • Airborne Alternaria spores are ubiquitous • Pigmented saprophytic mold (decaying vegetation) • Als

  9. Slide 9: CRS: An Immune Response to Fungi

    9 CRS: An Immune Response to Fungi CRS: An Immune Response to Fungi Electron microscopy image: Eosinophil (blue) releasing major basic protein as it comes into contact with a fungal hyphae (green). This toxic protein is damaging to both the fungus and the mucosal tissue of the sinus and nose.

  10. Slide 10: Eosinophils and Alternaria In Vitro

    10 Eosinophils and Alternaria In Vitro: eosinophils from normal patients are recruited by lymphocytes from patients with CS, but not lymphocytes from normals, to attack the fungus Eosinophils and Alternaria In Vitro: eosinophils from normal patients are recruited by lymphocytes from patients with CS

  11. Slide 11: Reactivity to fungus is responsible for CS

    11 Reactivity to fungus is responsible for CS Reactivity to fungus is responsible for CS Eosinophils target fungi in the mucin of CS patients. When that occurs, the eosinophils release toxic granule proteins, such as major basic protein (MBP). MBP in mucin indicates a reaction to the fungus. •70% of

  12. Slide 12: CRS Treatment Strategy: Topical Antifungals

    12 CRS Treatment Strategy: Topical Antifungals CRS Treatment Strategy: Topical Antifungals • Systemic antifungals associated with side effects • All side effects are dose related • Fungi are only in the mucus • Intranasal delivery would avoid systemic effects • Direct mucoadministration: high dose t

  13. Slide 13: SinuNase License

    13 SinuNase License SinuNase License Accentia’s License from the Mayo Foundation: Exclusive global license for intranasal Amphotericin B for CS Exclusive option to license all other antifungals until Dec 2008 Patent expires 2018: method of use for product and for diagnostic. Additional patents pendi

  14. Slide 14: SinuNase Study Summary

    14 SinuNase Study Summary SinuNase Study Summary (p<0.0012) Pump Spray 2003 Geneva University Study (Pump Spray) (p<0.04) SNOT-20 Lavage 2004 Mayo Clinic Study Double blind, randomized placebo controlled study (p=0.018) Pump Spray 2006 Corradini Study (Pump Spray) Objective Improvement? Subjective I

  15. Slide 15: Ebbens and Fokkens Study (JACI Nov 2006)

    15 Ebbens and Fokkens Study (JACI Nov 2006) Ebbens and Fokkens Study (JACI Nov 2006) No significant differences were observed after 13 weeks of treatment Results Primary outcomes included a reduction in total visual analog scale (VAS) score of symptoms and nasal endoscopy score. Endpoints 116 patien

  16. Slide 16: Emcur and Nasaline Devices

    16 Emcur and Nasaline Devices Emcur and Nasaline Devices

  17. Slide 17: SinuNase: Study Protocol Pivotal Phase 3

    17 SinuNase: Study Protocol Pivotal Phase 3 SinuNase: Study Protocol Pivotal Phase 3 Complete resolution of both cardinal symptoms Primary Endpoint Un-blinding and top line results 18 weeks after last patient enrolled Expected study period 120 days Study duration per patient At least 50 Number of st

  18. Slide 18: SinuNase Lavage Formulation

    18 SinuNase Lavage Formulation SinuNase Lavage Formulation Designed to allow ease of dispensing and low cost of goods Stable: room temp for 18+ months Simple: preparation consistent with ubiquitous saline lavages Demonstrated greatest in-vitro efficacy when compared to previously tested formulations

  19. Slide 19: What is the best delivery mechanism: Lavage>Spray>Nebulized

    19 What is the best delivery mechanism: Lavage>Spray>Nebulized 0.5 1.5 2.5 What is the best delivery mechanism: Lavage>Spray>Nebulized Miller, et al. Laryngoscope 114:February 2004

  20. Slide 20: Is ug/cc of Ampho B adequate?

    20 Is 100 ug/cc of Ampho B adequate? Is 100 ug/cc of Ampho B adequate? MIC50 for Amphotericin B is ~1ug/cc or 100X less than SinuNase clinical formulation Placebo control for SinuNase clinical trial has no antifungal effect in vitro from Pujol, et al. J. Antimicrobial Ther (2000) 46, 323-342 .

  21. Slide 21: Clinical Trial Enrollment and Randomization

    21 Clinical Trial Enrollment and Randomization Clinical Trial Enrollment and Randomization 2.5 Under ENT Care Post-Surgery CRS Moderate-to- Severe CRS Undiagnosed Total with CRS eMBP determination in the SinuNase phase 3 trial suggests that virtually 100% of cases of chronic sinusitis are due to fun

  22. Slide 22: Intent to Treat Analysis (ITT)

    22 Intent to Treat Analysis (ITT) Intent to Treat Analysis (ITT) N = 147 N = 143 Resolution of Congestion and Headache at Week 16 60% 20% 20% No Resolution Partial Resolution Complete Resolution Note: Includes subjects discontinued from randomization Change in Endoscopy Scores, by Nostril, from Scre

  23. Slide 23: Decrease in Endoscopy Scores (ITT; Week 16)

    23 Decrease in Endoscopy Scores (ITT; Week 16) Decrease in Endoscopy Scores (ITT; Week 16)

  24. Slide 24: CT Scan Results (ITT; Week 16)

    24 CT Scan Results (ITT; Week 16) CT Scan Results (ITT; Week 16) CT Scan Results at Week 16 57% 43% Decrease in Percent Mucosal Thickening Increase in Percent Mucosal Thickening n=115 (Note: Does not include all subjects discontinued from randomization)

  25. Slide 25: Decrease in Mucosal Thickening (ITT; Week 16)

    25 Decrease in Mucosal Thickening (ITT; Week 16) Decrease in Mucosal Thickening (ITT; Week 16)

  26. Slide 26: CT scan at baseline vs 16 weeks: SinuNase or Placebo Control?

    26 CT scan at baseline vs 16 weeks: SinuNase or Placebo Control? CT scan at baseline vs 16 weeks: SinuNase or Placebo Control? CT of maxillary sinus at enrollment CT of maxillary sinus at 16 weeks

  27. Slide 27: Saline Lavage Trials in Chronic Sinusitis (CS)

    27 Saline Lavage Trials in Chronis Sinusitis (CS) Saline Lavage Trials in Chronis Sinusitis (CS) 6 point visual analog scale: 0.3 pt. delta for each 6 point visual analog scale: 0.3 pt. delta for each Ems salt solution and saline Yes Bachmann (2000) Yes Yes CS Confirmed Polyposis recurred in 44% of

  28. Slide 28: Imputed % of SinuNase responders vs placebo responders

    28 Imputed % of SinuNase responders for any given % of placebo responders and the corresponding minimum SinuNase response rate for statistical significance. 0% 7% 10% 9% 19% 24% 40% 33% 30% 0% 5% 10% 15% 20% 25% 30% 35% 40% 45% Placebo Active (Minimum response for statistical significance) Imputed %

  29. Slide 29: Time of first reported resolution of congestion, headache, or both

    29 Time of first reported resolution of congestion, headache, or both, in subjects with resolution of both cardinal symptoms at 16 weeks Time of first reported resolution of congestion, headache, or both, in subjects with resolution of both cardinal symptoms at 16 weeks 32% 53% 74% 79% 84% 95% 100%

  30. Slide 30: Projected event timelines

    30 Projected event timelines 1 Aug 2 3 4 5 Patients Screened Projected event timelines First phase 3 study enrollment completed. 200+ patients qualified but for CT criterion Projected un-blinding: 18 weeks from completion of enrollment File for accelerated approval subpart E Commercial partnership f

  31. Slide 31: Fungal Etiology of CRS (ACAAI 2006)

    31 Fungal Etiology of CRS (ACAAI 2006) Fungal Etiology of CRS (ACAAI 2006) Survey Outcomes: Fungal Etiology of CRS? Fungal Etiology as Primary Cause? Surgical Population is where Fungal Etiology Most Likely? 74.9% Agree Disagree 37.4% Agree Disagree 83.6% Agree Disagree

  32. Slide 32: ENT Reports and Intranasal Antifungals

    32 ENT Reports and Intranasal Antifungals ENT Reports and Intranasal Antifungals At least 50% of ENTs and 50% of allergists reported using intranasal antifungals on their adult CS patients and/or surgery refractory CS patients. On average, 5% of adult CS patients and 7% of the surgery refractory CS

  33. Slide 33: Commercialization Strategy

    33 Commercialization Strategy Commercialization Strategy ABPI markets SinuNase to ENTs and Allergists • 15,000 in the USA •Market diagnostic and other products to them already •Currently 43 person sales force at ABPI Commercial co-promotion partnership with Pharma partner for primary care •80-90% of

  34. Slide 34: SinuNase Projected Revenues and Market User Base

    34 SinuNase Projected Revenues and Market User Base SinuNase Projected Revenues and Market (a) Assumed launch in 2009; 200,000 on off-label, 70% adoption rate of those patients @ $2500/pt/yr for first year, increasing by 30% on successive yrs.; 35 million Americans suffer from rhinosinusitis; approx

  35. Slide 35: Summary: Key Points on SinuNase

    35 Summary: 12 Key Points on SinuNase Summary: 12 Key Points on SinuNase 1. Largest untapped pharma market in US and EU is CS 2. No competitor in the pipeline 3. Patent-protected product 4. Patent-protected companion diagnostic 5. Well-tolerated formulation 6. Very low risk of adverse effects 7. Low

Accentia Biopharmaceuticals — Corporate Update (October 2007) on 6ix